141 related articles for article (PubMed ID: 25846456)
21. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
Fehniger JE; Berger AA; Juckett L; Elvin J; Levine DA; Zajchowski DA
Gynecol Oncol; 2019 Dec; 155(3):473-482. PubMed ID: 31703812
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
24. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer.
Hayano T; Yokota Y; Hosomichi K; Nakaoka H; Yoshihara K; Adachi S; Kashima K; Tsuda H; Moriya T; Tanaka K; Enomoto T; Inoue I
PLoS One; 2014; 9(12):e114491. PubMed ID: 25460179
[TBL] [Abstract][Full Text] [Related]
26. Clinical application of amplicon-based next-generation sequencing in cancer.
Chang F; Li MM
Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
[TBL] [Abstract][Full Text] [Related]
27. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
28. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
29. Cancer related gene alterations can be detected with next-generation sequencing analysis of bile in diffusely infiltrating type cholangiocarcinoma.
Lee CH; Wang HE; Seo SY; Kim SH; Kim IH; Kim SW; Lee ST; Kim DG; Han MK; Lee SO
Exp Mol Pathol; 2016 Aug; 101(1):150-6. PubMed ID: 27460275
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.
Ikeda S; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cancer Biol Ther; 2019; 20(2):219-226. PubMed ID: 30339521
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.
Cronin M; Ross JS
Biomark Med; 2011 Jun; 5(3):293-305. PubMed ID: 21657839
[TBL] [Abstract][Full Text] [Related]
32. LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
Xia Z; Cochrane DR; Anglesio MS; Wang YK; Nazeran T; Tessier-Cloutier B; McConechy MK; Senz J; Lum A; Bashashati A; Shah SP; Huntsman DG
Gynecol Oncol; 2017 Dec; 147(3):642-647. PubMed ID: 29032825
[TBL] [Abstract][Full Text] [Related]
33. Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
Sakai K; Ukita M; Schmidt J; Wu L; De Velasco MA; Roter A; Jevons L; Nishio K; Mandai M
Cancer Lett; 2017 Oct; 405():22-28. PubMed ID: 28734796
[TBL] [Abstract][Full Text] [Related]
34. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
35. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
[TBL] [Abstract][Full Text] [Related]
36. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
Wagle N; Berger MF; Davis MJ; Blumenstiel B; Defelice M; Pochanard P; Ducar M; Van Hummelen P; Macconaill LE; Hahn WC; Meyerson M; Gabriel SB; Garraway LA
Cancer Discov; 2012 Jan; 2(1):82-93. PubMed ID: 22585170
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy according to next generation sequencing-based panel sequencing.
Saito M; Momma T; Kono K
Fukushima J Med Sci; 2018 Apr; 64(1):9-14. PubMed ID: 29628467
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
Tran B; Brown AM; Bedard PL; Winquist E; Goss GD; Hotte SJ; Welch SA; Hirte HW; Zhang T; Stein LD; Ferretti V; Watt S; Jiao W; Ng K; Ghai S; Shaw P; Petrocelli T; Hudson TJ; Neel BG; Onetto N; Siu LL; McPherson JD; Kamel-Reid S; Dancey JE
Int J Cancer; 2013 Apr; 132(7):1547-55. PubMed ID: 22948899
[TBL] [Abstract][Full Text] [Related]
39. Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers.
Watson CH; Broadwater G; Wong J; Spinosa D; de Oca MKM; Datto M; Green M; Hubbard C; McKinney M; McCall SJ; Havrilesky LJ; Strickler JH; Berchuck A; Strickland KC; Previs RA
Target Oncol; 2021 Jan; 16(1):109-118. PubMed ID: 33400095
[TBL] [Abstract][Full Text] [Related]
40. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics.
Helsten T; Kato S; Schwaederle M; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R
Mol Cancer Ther; 2016 Jul; 15(7):1682-90. PubMed ID: 27196769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
